Ticagrelor is an antagonist of the adenosine diphosphate receptors, which is indicated in patients with acute coronary syndrome and in perukutaneous coronary intervention (PCI) and aortocoronary bypass surgery. It is administered together with acetylsalicylic acid.
Ticagrelor
DefinitionThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Initial dose of 180 milligrams, then two 90 milligrams + ASA.
Undesirable effectsThis section has been translated automatically.
Rarely respiratory distress, occasional bradycardia.
Unlike clopidogrel and prasugrel, ticagrelor reversibly blocks the ADP receptor. Total cardiovascular mortality is reduced by 1% compared to clopidogrel. Bleeding requiring treatment is 1-2% more frequent with ticagrelor than with clopidogrel. Severe and fatal bleeding are equally frequent.
InteractionsThis section has been translated automatically.
Interactions with Clarithromycin; Rifampicin, Dexamethasone, Carbamapezine and others
PreparationsThis section has been translated automatically.
Brilique®
LiteratureThis section has been translated automatically.
- HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin